Canada Drugstore Pharmacies Support the Fight against Alzheimer's Disease

If neglected, the number of Alzheimer's patients could triple by 2050.  Hence, Canada drugs  will surely play a big role in stopping such increase. 

"The idea behind the plan is to develop a coordinated effort to solve the Alzheimer's problem," said William Thies, vice president for medical and scientific affairs at the Alzheimer's Association. 

"We recognize that the demographic imperative is going to happen with the peak of the epidemic in 2050," Thies said. By that date, it's estimated that 16 million Americans may be suffering from Alzheimer's disease, he added. 

"We are struggling to manage the number we have now, which is a little over 5 million. So you can imagine with three times as many [patients], current systems simply can't manage that increase. It points to a very bleak future if we don't do something pretty quickly as the baby boom population starts developing more Alzheimer's disease," he said. 

"We are going to have a plan. We don't know what it's going to look like. The [Alzheimer's] Association is committed to get the best plan that is possible. And if the plan isn't good enough we will not keep that a secret," he said.  But as of the moment, the best thing to do for Alzheimer’s patients is to  buy Aricept . 

"While it is always helpful to call attention to the disease, I worry that efforts like these are mostly window-dressing," said Dr. Sam Gandy, Mount Sinai Professor of Alzheimer's Disease Research at Mount Sinai Hospital in New York City. 

"There are no funds attached, and there are no basic scientists on the panel. I don't see how they can seriously discuss cure without basic science input. I would also say that 2025 is way, way too optimistic," he said. 

Greg M. Cole, a neuroscientist at the Greater Los Angeles VA Healthcare System, said the panel's goals are certainly worthy -- to be able to diagnose the disease early and provide support for caregivers and their families.

"But many people won't seek early diagnosis without more powerful treatments that do more than provide temporary symptomatic relief," he said. "Who wants someone to confirm a dreaded diagnosis with no expectation that they can beat this disease?" 

"The diagnostic methods that have received the most government support use expensive imaging methods that would cost a fortune to implement on a mass scale. We need cheaper methods to screen an aging population," he said.  In addition,  Canada pharmacies  support this drive by stocking meds as prescribed by the physicians. 

"Most of the current approaches in the pipeline -- like passive immunization with antibodies -- are likely to be very expensive at tens of thousands of dollars per year per patient," he said. "Therefore they are not very suitable for prevention in an era of limited resources." 

"Drug companies will invest far more than government in finding new treatments. If the past is any guide, they will provide better tools for disease management but with increased costs," he said. 

A plan that addresses the medical costs of dementia in an aging population has to center on prevention, Cole said. "There should be far more government resources aimed at a serious efforts at finding and implementing low-cost prevention methods," he said. 

"The new criteria no longer require a dementia diagnosis while the person was living, as studies suggest that Alzheimer's develops years before it becomes clinically evident and research has revealed that the brains of even cognitively normal people may have Alzheimer's-related brain changes," the NIH said in a news release Wednesday.